Delving into the Latest Updates on IGF Oncology LLC with Synapse

Overview

Tags

Congenital Disorders

Immune System Diseases

Endocrinology and Metabolic Disease

Antibody drug conjugate (ADC)

Peptide drug conjugates

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Antibody drug conjugate (ADC)	1
Peptide drug conjugates	1

Top 5 Target	Count

IGF-1(Insulin-like growth factor I)	1
FOLR1 x IGF-1	1

The primary objective of this study is to determine the safety and tolerability of utilizing the insulin-like growth factor-1-methotrexate conjugate, 765IGF-MTX for the treatment of advanced, previously treated myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and oligoblastic acute myelogenous leukemia (oligoblastic AML or O-AML), including determining the maximum tolerated dose (MTD).

Start Date21 Feb 2018

Sponsor / Collaborator

IGF Oncology LLC

NCT02045368 / CompletedPhase 1

STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing Insulin-like Growth Factor Receptor 1 (IGF-1R)

This phase I dose escalation study will evaluate IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated tumors. 765IGF-MTX is administered as an IV infusion over 1 hour on days 1, 8 and 15 of a 28 day cycle. Treatment continues until disease progression, unacceptable toxicity, or patient refusal. Assessment of response will be confirmed with imaging studies performed at the end of cycle 2 +/- 7 days, and every 2 weeks thereafter.

Start Date28 Jan 2014

Sponsor / Collaborator

IGF Oncology LLC

100 Clinical Results associated with IGF Oncology LLC

Login to view more data

0 Patents (Medical) associated with IGF Oncology LLC

Login to view more data

1

Literatures (Medical) associated with IGF Oncology LLC

01 Nov 2019·American Journal of Clinical OncologyQ4 · MEDICINE

Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R

Q4 · MEDICINE

Article

Author: Chowdhery, Rozina ; Russell, Meredith J ; Emmadi, Rajyasree ; Gaitonde, Sujata ; Dudek, Arkadiusz Z ; Zaidi, Ayesha ; Kothari, Rajul ; Fischer, James H ; Cabay, Robert J ; Danciu, Oana C ; Aardsma, Nathan ; Liu, Li C ; Venepalli, Neeta K

Objectives:Insulin-like growth factor-methotrexate (IGF-MTX) is a conjugate of methotrexate and 765IGF, a variant of IGF-1 with high affinity for insulin-like growth factor type 1 receptor. The study aim was to determine the maximum tolerated dose of IGF-MTX in refractory solid organ and hematologic malignancies expressing insulin-like growth factor type 1 receptor.Materials and Methods:This phase I trial used a modified toxicity probability interval design with 5 cohort dose levels, and expansion cohort at maximum tolerated dose. IGF-MTX was given intravenously over 90 minutes on days 1, 8, and 15 of a 28-day cycle.Results:A total of 17 patients were enrolled. The highest tolerated dose tested was 0.80 µEq/kg with dose-limiting toxicity of grade 3 hypoglycemia. Drug-related grade 3 and 4 toxicities included abdominal pain (26%), hypoglycemia (10%), and hypotension (10%). Of the 15 evaluable for response, 3 patients (20%) had stable disease, including the patient with Hodgkin lymphoma with stable disease for 12 cycles of therapy. IGF-MTX concentrations declined rapidly, with half-lives of 5.2 to 14 minutes for the initial distribution phase and 6.5 to 7.5 hours for the terminal elimination phase. Higher IGF-R1 expression did not correlate with better outcome.Conclusions:IGF-MTX is well tolerated. IGF-MTX pharmacokinetics suggest rapid cellular uptake. The activity of IGF-MTX in Hodgkin lymphoma should be explored.

100 Deals associated with IGF Oncology LLC

Login to view more data

100 Translational Medicine associated with IGF Oncology LLC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

IND Application

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LX-101(Lirum Therapeutics) ( FOLR1 x IGF-1 )	Graves Ophthalmopathy More	IND Application
IGF-drug conjugates(IGF Oncology LLC) ( IGF-1 )	Neoplasms More	Preclinical